<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661124</url>
  </required_header>
  <id_info>
    <org_study_id>S-2018-3</org_study_id>
    <nct_id>NCT04661124</nct_id>
  </id_info>
  <brief_title>Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position</brief_title>
  <official_title>Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg Engineering GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg Engineering GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical study conducted at one clinical site in the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are to:&#xD;
&#xD;
        1. Compare the image quality of images between the SPECTRALIS with Flex Module and the&#xD;
           SPECTRALIS.&#xD;
&#xD;
        2. &amp; 3. Assess the agreement in the ability to identify abnormalities between the&#xD;
           SPECTRALIS with Flex Module images and the SPECTRALIS images.&#xD;
&#xD;
      The secondary objective is to evaluate any adverse events found during the clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The image quality grade of the acquired images as determined by an independent reading center</measure>
    <time_frame>through study completion, average of 1 day</time_frame>
    <description>OCT, OCTA and IR cSLO - graded Good (2)/Average (1)/Poor (0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agreement in identification of abnormalities of the acquired Standard OCT images between the devices</measure>
    <time_frame>through study completion, average of 1 day</time_frame>
    <description>based on pre-specified abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agreement in identification of abnormalities of the acquired OCTA images between the devices</measure>
    <time_frame>through study completion, average of 1 day</time_frame>
    <description>based on pre-specified abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion, average of 1 day</time_frame>
    <description>All AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Healthy Eyes</condition>
  <arm_group>
    <arm_group_label>Adult Normal Eyes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Pathology Eyes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPECTRALIS</intervention_name>
    <description>ophthalmic imaging device with head and chinrest</description>
    <arm_group_label>Adult Normal Eyes</arm_group_label>
    <arm_group_label>Adult Pathology Eyes</arm_group_label>
    <other_name>SPECTRALIS HRA+OCT (and variants) with OCT Angiography Module</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPECTRALIS with Flex Module</intervention_name>
    <description>ophthalmic imaging device on mobile instrumentation stand</description>
    <arm_group_label>Adult Normal Eyes</arm_group_label>
    <arm_group_label>Adult Pathology Eyes</arm_group_label>
    <other_name>SPECTRALIS HRA+OCT (and variants) with Flex Module</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Adult Normal Eyes Population (AN)&#xD;
&#xD;
        Inclusion Criteria for AN Population&#xD;
&#xD;
          1. Age ≥ 22 years&#xD;
&#xD;
          2. Able and willing to undergo the test procedures, sign informed consent, and follow&#xD;
             instructions.&#xD;
&#xD;
          3. Physically able to be positioned in all required imaging positions (upright at&#xD;
             chinrest and supine).&#xD;
&#xD;
          4. Able to fixate.&#xD;
&#xD;
          5. Best corrected visual acuity ≥ 20/40 in both eyes.&#xD;
&#xD;
        Exclusion Criteria for AN Population&#xD;
&#xD;
          1. Eye with ocular media not sufficiently clear to obtain acceptable study-related&#xD;
             imaging.&#xD;
&#xD;
          2. Subjects who cannot tolerate the imaging procedures.&#xD;
&#xD;
          3. Clinically significant ocular disease in either eye as determined by an Investigator.&#xD;
&#xD;
          4. Ocular surgical intervention (except for refractive laser surgery or cataract surgery)&#xD;
             in either eye.&#xD;
&#xD;
        Adult Posterior Segment Abnormality Eye Population (AD)&#xD;
&#xD;
        Inclusion Criteria for AD Population&#xD;
&#xD;
          1. Age ≥ 22 years&#xD;
&#xD;
          2. Able and willing to undergo the test procedures, sign informed consent, and follow&#xD;
             instructions.&#xD;
&#xD;
          3. Physically able to be positioned in all required imaging positions (upright at&#xD;
             chinrest and supine).&#xD;
&#xD;
          4. Able to fixate.&#xD;
&#xD;
          5. Eye with a structural and vascular posterior segment abnormality due to ocular disease&#xD;
             and/or trauma.&#xD;
&#xD;
        Exclusion Criteria for AD Population&#xD;
&#xD;
          1. Eye with ocular media not sufficiently clear to obtain acceptable study-related&#xD;
             imaging.&#xD;
&#xD;
          2. Subjects who cannot tolerate the imaging procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lejla Vajzovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie M Leung</last_name>
    <phone>800-931-2230</phone>
    <email>valerie.leung@heidelbergengineering.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Jones</last_name>
    </contact>
    <investigator>
      <last_name>Lejla Vajzovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

